Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 676

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 676
---
 neuromas, noncancerous growths that develop along the auditory nerve. There are currently no approved therapeutics for this disease, Therefore, it is expected that VXM01 can be applied to Neurofibromatosis and prove its efficacy in treating Neurofibromatosis.                            |

F-135

33. Business combinations (cont.) (2) VXM-Preclinical VAXIMM’s preclinical programs are composed of 4 different pipelines: VXM04, VXM06, VXM08 and VXM10 •VXM04 carries human mesothelin as the target antigen. Mesothelin is a protein that is overexpressed in several solid tumors. •VXM06 targets WT1. WT1 is overexpressed in several hematological malignancies and solid tumors. In preclinical studies, VXM06 has shown potent T -cellactivation against WT1 and stand -alonetherapeutic activity in models of leukemia. •VXM08 targets CEA, a human tumor -associatedantigen overexpressed in many solid tumors. In preclinical studies, VXM08 has shown potent T -cellactivation against its target antigen as well as stand -alonetherapeutic activity in models of colorectal and lung cancer. •VXM10 targets PD -L1, an immunomodulatory antigen upregulated in many solid tumors as well as hematological malignancies. VXM10 is currently in preclinical development and has shown stand -alonetherapeutic activity in models of leukemia. 33.4 Net cashflow from acquisition for the years ended December 31, 2023 and 2022 are as follows:

| (Korean won in unit)                                    |     |                    2023 |   |
| Net cash outflow arising from acquisition of Darnatein: |     |                         |   |
| Cash consideration                                      |     |           ₩           — |   |
| Less: cash and cash equivalent balances acquired        |     |             (88,452,978 | ) |
|                                                         |     | ₩           (88,452,978 | ) |

| (Korean won in unit)                                         |     |                2022 |   |
| Net cash outflow arising from acquisition of VAXIMM and RMC: |     |                     |   |
| Cash consideration                                           |     |       ₩           — |   |
| Less: cash and cash equivalent balances acquired             |     |      (2,249,584,